A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries

Kjær, Susanne K.; Nygård, Mari; Dillner, Joakim; Marshall, J. Brooke; Radley, David; Li, Meng; Munk, Christian; Hansen, Bo T.; Sigurðardóttir, Lára G.; Hortlund, Maria; Tryggvadóttír, Laufey; Joshi, Amita; Das, Rituparna; Saah, Alfred J.

doi:10.1093/cid/cix797

Cited by 108 publications

(75 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was assumed that the HPV vaccination would not change the natural course of HPV infection or disease prevalence at the time of vaccination. Also, we assumed that the duration of protection of HPV vaccination would be lifelong …”

Section: Methodsmentioning

confidence: 99%

“…Also, we assumed that the duration of protection of HPV vaccination would be lifelong. 22,23 The outcome measures of the study were: (1) additional reduction in the prevalence of vaccine-related HPV-type infection and burden of their related genital warts, CIN and cervical cancer and (2) incremental cost-effectiveness ratio (ICER) of vaccination with nonavalent HPV vaccination in a school-based programme involving adolescent girls between 11 and 12 years old, compared with similar strategies with quadrivalent or bivalent HPV vaccination. It was assumed that the vaccine coverage was 80% for all the strategies, based on long-term experience of more than 90% uptake rate of childhood immunisation in Singapore.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and economic impact of school‐based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis

Tay

Hsu

Pavelyev³

et al. 2018

BJOG

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Clinical and economic impact of school‐based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis

Tay

Hsu

Pavelyev³

et al. 2018

BJOG

View full text Add to dashboard Cite

show abstract

“…These vaccines induce persistent high titers of antibody against the vaccine strains of HPV, and several lines of evidence suggest that HPV type-specific antibodies are responsible for efficacy of the vaccine [14,15]. Efficacy after vaccination has been established thus far for 8–10 years [16]. During this interval levels of HPV-specific antibody decline, but remain above levels characteristic of protection after natural infection [17–19].…”

Section: Introductionmentioning

confidence: 99%

Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine

Levin

Huang

Moscicki

et al. 2017

Vaccine

View full text Add to dashboard Cite

Objective Although HIV-infected children are recommended to receive quadrivalent human papillo-mavirus vaccine (QHPV) there is limited information on their response to QHPV. This study in HIV-infected children, evaluated the magnitude and duration of immune responses to QHPV. This report describes type-specific serum antibody responses over a 4-to-5 year period after either 3 or 4 doses of QHPV. Design/methods HIV-infected children, ages 7-to-11 years, received 3 doses of QHPV (n = 96) or placebo (n = 30). At 72 weeks QHPV recipients received a fourth dose (n = 84), while placebo recipients began the 3-dose QHPV schedule (n = 27). HPV serotype-specific antibody was determined, by competitive Luminex immunoassay (cLIA) and IgG Luminex immunoassay, at 2, 3.5, and 4-to-5 years after the last dose of QHPV in each treatment arm. Results At 4-to-5 years after the last dose of QHPV, antibody titers were significantly higher in 4-dose than in 3-dose group. However, the proportion of vaccinees with a seroresponse in the cLIA assay was not different between the two groups (86–93% for HPV types 6, 11, and 16, and 64% for HPV type 18). These results were very similar to the seroresponse rate in these HIV-infected children at 1 month after completing vaccination. Conclusions Children with well-controlled HIV infection who receive 3 doses of the QHPV vaccine maintain seropositivity and antibody levels that are generally similar to children of the same age who are not HIV-infected. Antibody titer correlated strongly with low log HIV RNA, low CD8%, and high CD4%. Additionally, a fourth dose of vaccine in HIV-infected children produces a marked rise in antibody characteristic of an anamnestic response and persistence of high antibody levels. Conclusions Study identification: IMPAACT P1085 (V501-021). CLINICALTRIALS.GOV identifier: NCT01206556.

show abstract

“…Data from cohort of vaccinated individuals suggest that the vaccine offers protection for at least 10-12 years [9,15]. Moreover, unlike natural infection, the vaccine confers crossprotection against heterologous HPV types.…”

Section: Introductionmentioning

confidence: 99%

Assessing the Impact of Prophylactic Vaccines on HPV Prevalence

Azevedo¹,

Esteva²,

Ferreira³

2019

Tend. Mat. Apl. Comput.

View full text Add to dashboard Cite

A mathematical model considering female and male individuals is proposed to evaluate vaccination strategies applied to control of HPV transmission in human population. The basic reproductive number of the disease, R 0 , is given by the geometric mean of the basic reproductive number of female and male populations. The model has a globally asymptotically stable disease-free equilibrium whenever R 0 < 1. Furthermore, it has an unique endemic state when R 0 exceeds unity which is globally asymptotically stable. Numerical simulations were done to compare several different vaccination schedules. The results showed that the vaccination strategies that do not include vaccination of men can only control the disease if more than 90% of women are vaccinated. The sensitivity analysis indicated that the relevant parameters to control HPV transmission, in order of importance, are vaccine efficacy times the fraction of population that is vaccinated, disease recovery-rate, and disease transmission rate. Therefore, health politics that promoting the increase of vaccine coverage, and screening for the disease in both population can improve disease control.

show abstract

A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries

Abstract: V501-015.

Cited by 108 publications

References 19 publications

Clinical and economic impact of school‐based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis

Clinical and economic impact of school‐based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis

Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine

Assessing the Impact of Prophylactic Vaccines on HPV Prevalence

Contact Info

Product

Resources

About